Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 10/20 | 0.71 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | ESR1 | P03372 | 2/20 | 0.71 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.71 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.71 |
| ▸ | SHBG | P04278 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | PGR | P06401 | 1/20 | 0.71 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.71 |
| ▸ | AR | P10275 | 1/20 | 0.71 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.71 |
| ▸ | SNCA | P37840 | 1/20 | 0.71 |
| ▸ | HTR2B | P41595 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13951936 | 1.00 | STS (0.71) | STSHSD17B1LMNAMAPTESR1 | |
| SCHEMBL9611189 | 0.88 | STS (0.71) | STSHSD17B1LMNAMAPTESR1 | |
| SCHEMBL9611187 | 0.87 | STS (0.69) | STSHSD17B1LMNAMAPTESR1 | |
| Estrone SCHEMBL17419460 | 0.85 | HSD17B1 (0.89) | STSHSD17B1LMNAMAPTESR1 | |
| Estrone SCHEMBL9765070 | 0.84 | HSD17B1 (0.97) | STSHSD17B1LMNAMAPTESR1 | |
| Estrone SCHEMBL9765071 | 0.84 | HSD17B1 (0.97) | STSHSD17B1LMNAMAPTESR1 | |
| SCHEMBL16782654 | 0.84 | STS (0.67) | STSHSD17B1LMNAMAPTESR1 | |
| SCHEMBL217968 | 0.83 | HSD17B1 (0.76) | STSHSD17B1LMNAMAPTESR1 | |
| Estrone SCHEMBL7831317 | 0.83 | CYP19A1 (1.00) | STSHSD17B1LMNAMAPTESR1 | |
| Estrone SCHEMBL5028951 | 0.83 | CYP19A1 (1.00) | STSHSD17B1LMNAMAPTESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2958928-B1 | ESTRA-1,3,5(10),16-TETRAENE-3-CARBOXAMIDES FOR INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASE (AKR1 C3) | Bayer Pharma AG (DE) | 2018-03-28 | — | — | EP | disclosed |
| EP-2958928-B1 | ESTRA-1,3,5(10),16-TETRAENE-3-CARBOXAMIDES FOR INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASE (AKR1 C3) | Bayer Pharma AG (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-9714266-B2 | Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-25 | — | — | US | disclosed |
| US-9714266-B2 | Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-25 | — | — | US | disclosed |
| US-9714266-B2 | Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-25 | — | — | US | disclosed |
| US-20160024142-A1 | ESTRA-1,3,5(10),16-TETRAENE-3-CARBOXAMIDES FOR INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASE (AKR1 C3) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | US | disclosed |
| US-20160024142-A1 | ESTRA-1,3,5(10),16-TETRAENE-3-CARBOXAMIDES FOR INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASE (AKR1 C3) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | US | disclosed |
| US-20160024142-A1 | ESTRA-1,3,5(10),16-TETRAENE-3-CARBOXAMIDES FOR INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASE (AKR1 C3) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | US | disclosed |
| EP-2958928-A1 | ESTRA-1,3,5(10),16-TETRAENE-3-CARBOXAMIDES FOR INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASE (AKR1 C3) | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-30 | — | — | EP | disclosed |
| WO-2014128108-A1 | ESTRA-1,3,5(10),16-TETRAENE-3-CARBOXAMIDES FOR INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASE (AKR1 C3) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024142-A1 | ESTRA-1,3,5(10),16-TETRAENE-3-CARBOXAMIDES FOR INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASE (AKR1 C3) | AKR1C3, AKR1A1, AKR1C1 | STS 111/4885HSD17B1 12/4885LMNA 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.